BioPharma Dive
verified

BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships.

BioPharma Dive
flipped into BioPharma Dive
15 hours ago
Bristol Myers says schizophrenia drug launch ‘off to a solid start’
biopharmadive.com - Jacob Bell
A new, closely watched schizophrenia medication from Bristol Myers Squibb sold well in its first full quarter on the market, according to both the …
BioPharma Dive
flipped into BioPharma Dive
15 hours ago
Merck takes $200M tariff hit, trimming its gross profits
biopharmadive.com - Jonathan Gardner
Dive Brief:• Merck & Co. “absorbed” $200 million in addition expenses related to U.S. and overseas tariffs in the first quarter of 2025, increasing its …
BioPharma Dive
flipped into Pharma
16 hours ago
Sanofi stays course amid tariff turmoil
biopharmadive.com - Kristin Jensen
Dive Brief:• Sanofi’s first-quarter sales and profit exceeded analyst expectations, but the company held tight on its full-year guidance amid looming …
BioPharma Dive
flipped into BioPharma Dive
17 hours ago
Versant startup Granite debuts with $100M and two immune drugs
biopharmadive.com - Gwendolyn Wu
Venture capitalists have been scouring the globe in search of better immunology drugs. Biotech startup creator Versant Ventures is among them, having …
BioPharma Dive
flipped into BioPharma Dive
21 hours ago
Etiome, a new Flagship startup, looks to catch disease before it strikes
biopharmadive.com - Gwendolyn Wu
Flagship Pioneering unveiled its latest biotechnology startup on Thursday, a company aiming to map the progression of diseases and tailor medicines …
BioPharma Dive
flipped into Biotech
1 day ago
German antibody maker valued at $1.6B in blank-check merger
biopharmadive.com - Kristin Jensen
Dive Brief:• Veraxa Biotech, a cancer therapy developer backed by Swiss incubator Xlife Sciences, will go public through a combination with a …